Aptose Biosciences Inc. APS.TO Stock
Aptose Biosciences Inc. Price Chart
Aptose Biosciences Inc. APS.TO Financial and Trading Overview
Aptose Biosciences Inc. stock price | 1.9 CAD |
Previous Close | 7.94 CAD |
Open | 7.85 CAD |
Bid | 7.78 CAD x N/A |
Ask | 7.89 CAD x N/A |
Day's Range | 7.64 - 7.9 CAD |
52 Week Range | 7.22 - 18.6 CAD |
Volume | 4.22K CAD |
Avg. Volume | 1.89K CAD |
Market Cap | 49.36M CAD |
Beta (5Y Monthly) | 1.677149 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -10.38 CAD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 99.86 CAD |
APS.TO Valuation Measures
Enterprise Value | 666.03M CAD |
Trailing P/E | N/A |
Forward P/E | -0.8574538 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 28.243727 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -14.774 |
Trading Information
Aptose Biosciences Inc. Stock Price History
Beta (5Y Monthly) | 1.677149 |
52-Week Change | -52.67% |
S&P500 52-Week Change | 20.43% |
52 Week High | 18.6 CAD |
52 Week Low | 7.22 CAD |
50-Day Moving Average | 9.62 CAD |
200-Day Moving Average | 12.01 CAD |
APS.TO Share Statistics
Avg. Volume (3 month) | 1.89K CAD |
Avg. Daily Volume (10-Days) | 4.58K CAD |
Shares Outstanding | 6.26M |
Float | 81.09M |
Short Ratio | 9.71 |
% Held by Insiders | N/A |
% Held by Institutions | N/A |
Shares Short | 12.76K |
Short % of Float | 0.20% |
Short % of Shares Outstanding | 0.20% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -50.47% |
Return on Equity (ttm) | -96.44% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -45082000 CAD |
Net Income Avi to Common (ttm) | -44018000 CAD |
Diluted EPS (ttm) | -9.09 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 35.72M CAD |
Total Cash Per Share (mrq) | 0.38 CAD |
Total Debt (mrq) | 1.22M CAD |
Total Debt/Equity (mrq) | 4.71 CAD |
Current Ratio (mrq) | 3.054 |
Book Value Per Share (mrq) | 0.279 |
Cash Flow Statement
Operating Cash Flow (ttm) | -33979000 CAD |
Levered Free Cash Flow (ttm) | -17715750 CAD |
Profile of Aptose Biosciences Inc.
Country | Canada |
State | ON |
City | Toronto |
Address | 251 Consumers Road |
ZIP | M2J 4R3 |
Phone | 647-479-9828 |
Website | https://www.aptose.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 35 |
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Q&A For Aptose Biosciences Inc. Stock
What is a current APS.TO stock price?
Aptose Biosciences Inc. APS.TO stock price today per share is 1.9 CAD.
How to purchase Aptose Biosciences Inc. stock?
You can buy APS.TO shares on the Toronto exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Aptose Biosciences Inc.?
The stock symbol or ticker of Aptose Biosciences Inc. is APS.TO.
Which industry does the Aptose Biosciences Inc. company belong to?
The Aptose Biosciences Inc. industry is Biotechnology.
How many shares does Aptose Biosciences Inc. have in circulation?
The max supply of Aptose Biosciences Inc. shares is 15.72M.
What is Aptose Biosciences Inc. Price to Earnings Ratio (PE Ratio)?
Aptose Biosciences Inc. PE Ratio is now.
What was Aptose Biosciences Inc. earnings per share over the trailing 12 months (TTM)?
Aptose Biosciences Inc. EPS is -10.38 CAD over the trailing 12 months.
Which sector does the Aptose Biosciences Inc. company belong to?
The Aptose Biosciences Inc. sector is Healthcare.